##################################################################################
# Document Properties
##################################################################################
SET DOCUMENT Name = "32147628.bel"
SET DOCUMENT Authors = "Geena Mariya Jose"
SET DOCUMENT ContactInfo = "geena.mariya.jose@causalitybiomodels.com"
SET DOCUMENT Description = "COVID Knowledge Curation project"

SET DOCUMENT Licenses = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT Copyright = "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved"
SET DOCUMENT Version = "2.0.0"


##################################################################################
# NAMESPACES Section
##################################################################################

# DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"

# DEFINE NAMESPACE ADO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns"
# DEFINE NAMESPACE BRCO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns"
# DEFINE NAMESPACE NIFT AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/nift/NIFT.belns"

DEFINE NAMESPACE HGNC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns"
# DEFINE NAMESPACE MGI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20190128.belns"
# DEFINE NAMESPACE RGD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20190128.belns"
# DEFINE NAMESPACE GFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-genefamily-names-20181221.belns"
# DEFINE NAMESPACE SCOMP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20190128.belns"
# DEFINE NAMESPACE SFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20190128.belns"
# DEFINE NAMESPACE HP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20190130.belns"
DEFINE NAMESPACE CHEBI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns"
DEFINE NAMESPACE TAX AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
DEFINE NAMESPACE DRUGBANK AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/drugbank/drugbank-20180906.belns"
# DEFINE NAMESPACE INTERPRO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-names-20181021.belns"
# DEFINE NAMESPACE PFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/pfam/pfam-names-20181024.belns"
DEFINE NAMESPACE DO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns"
DEFINE NAMESPACE GO AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns"
DEFINE NAMESPACE GOBP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns"
# DEFINE NAMESPACE GOCC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20190128.belns"

DEFINE NAMESPACE MESH AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns"

# DEFINE NAMESPACE MESHC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20190128.belns"
# DEFINE NAMESPACE MESHD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20190128.belns"
DEFINE NAMESPACE MESHPP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns"
# DEFINE NAMESPACE MESHA AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-anatomy/mesh-anatomy-20190128.belns"
# DEFINE NAMESPACE MESHCS AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cellular-structures/mesh-cellular-structures-20190128.belns"
# DEFINE NAMESPACE NCBITAXON AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

DEFINE NAMESPACE NCBIGENE AS PATTERN ".*"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"
# DEFINE NAMESPACE dbSNP AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE FIXME AS PATTERN ".*"

##################################################################################
# ANNOTATIONS Section
##################################################################################

# DEFINE ANNOTATION Anatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20190128.belanno"
# DEFINE ANNOTATION CellLine AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20190128.belanno"
# DEFINE ANNOTATION Cell AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20190128.belanno"
# DEFINE ANNOTATION Disease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20190128.belanno"
DEFINE ANNOTATION MeSHAnatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20190128.belanno"
DEFINE ANNOTATION MeSHDisease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20190128.belanno"
DEFINE ANNOTATION Species AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
# DEFINE ANNOTATION TextLocation AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
# DEFINE ANNOTATION BioAssay AS PATTERN ".*"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"

DEFINE ANNOTATION Study AS LIST {"in silico"}

# Document Annotations #
DEFINE ANNOTATION PublicationType AS LIST {"Communication"}
DEFINE ANNOTATION PublicationStatus AS LIST {"Published"}
DEFINE ANNOTATION Section AS LIST {"Full Text"}

##################################################################################
# Statements #
##################################################################################

SET Citation = {"PubMed","32147628"}
SET PublicationType = "Communication"
SET PublicationStatus = "Published"
SET Section = "Full Text"

SET Evidence = "The fifth edition of the Guidelines recommends antivirals including IFN-α, lopinavir/ritonavir, and ribavirin for treatment of COVID-19 (3)."
a(PUBCHEM:347910052) -| path(DO:"COVID-19")
a(CHEBI:lopinavir) -| path(DO:"COVID-19")
a(CHEBI:ritonavir) -| path(DO:"COVID-19")
a(CHEBI:ribavirin) -| path(DO:"COVID-19")

SET Evidence = "Chloroquine phosphate and arbidol are included in the sixth edition of the Guidelines based on the preliminary outcomes of clinical studies (2)."
a(PUBCHEM:64927) -| path(DO:"COVID-19")
a(PUBCHEM:131411) -| path(DO:"COVID-19")

SET Evidence = "IFN-α is a broad-spectrum antiviral that is usually used to treat hepatitis, though it is reported to inhibit SARS-CoV reproduction in vitro (4)."
a(PUBCHEM:347910052) -| path(DO:hepatitis)
a(PUBCHEM:347910052) -| a(TAX:"Severe acute respiratory syndrome-related coronavirus")

SET Evidence = "Lopinavir/ritonavir is a medication for the human immunodeficiency virus (HIV) used in combination with other medications to treat adults and children over 14 days of age who are infected with HIV-1 (5)."
a(CHEBI:lopinavir) -| a(TAX:"Human immunodeficiency virus")
a(CHEBI:ritonavir) -| a(TAX:"Human immunodeficiency virus")

SET Evidence = "Chu et al. found that lopinavir/ ritonavir has anti-SARS-CoV activity in vitro and in clinical studies (6)."
a(CHEBI:lopinavir) -| a(TAX:"Severe acute respiratory syndrome-related coronavirus")
a(CHEBI:ritonavir) -| a(TAX:"Severe acute respiratory syndrome-related coronavirus")

SET Evidence = "A study compared 111 patients with severe acute respiratory syndrome (SARS) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ ritonavir and ribavirin; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome (ARDS) and death (6)."
SET Species = "9606"
composite(a(CHEBI:lopinavir),a(CHEBI:ribavirin)) -| path(DO:"adult respiratory distress syndrome")
composite(a(CHEBI:ritonavir),a(CHEBI:ribavirin)) -| path(DO:"adult respiratory distress syndrome")
UNSET Species

SET Evidence = "Chloroquine was found to block SARS-CoV-2 infection at low micromolar concentration, with a half-maximal effective concentration (EC50) of 1.13 μM and a half-cytotoxic concentration (CC50) greater than 100 μM (8)."
a(CHEBI:chloroquine) -| a(TAX:"Severe acute respiratory syndrome-related coronavirus")

SET Evidence = "A study has revealed that arbidol can effectively inhibit SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9)."
a(PUBCHEM:131411) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")

SET Evidence = "Favipiravir was approved for treatment of novel influenza on February 15, 2020 in China."
a(CHEBI:favipiravir) -| path(DO:influenza)

SET Evidence = "The preliminary results from a total of 80 patients (including the experimental group and the control group) indicated that favipiravir had more potent antiviral action than that of lopinavir/ritonavir (12)."
SET Species = "9606"
a(CHEBI:favipiravir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
UNSET Species

SET Evidence = "Remdesivir is another potential drug for treatment of COVID-19."
a(PUBCHEM:121304016) -| path(DO:"COVID-19")

SET Evidence = "Animal experiments (13) indicated that remdesivir can effectively reduce the viral load in lung tissue of mice infected with MERSCoV, improve lung function, and alleviate pathological damage to lung tissue."
SET MeSHAnatomy = "Lung"
a(PUBCHEM:121304016) -| a(TAX:"Middle East respiratory syndrome-related coronavirus")
UNSET MeSHAnatomy

SET Evidence = "Wang et al. found that remdesivir potently blocks SARS-CoV-2 infection at low micromolar concentrations and has a high selectivity index (half-maximal effective concentration (EC50), 0.77 μM; half-cytotoxic concentration (CC50) > 100 μM; SI > 129.87) (8)."
a(PUBCHEM:121304016) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")

SET Evidence = "On February 4, 2020, researchers in China announced that darunavir inhibited SARS-CoV-2 infection in vitro (9)."
a(CHEBI:darunavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")

SET Evidence = "Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 μM in vitro and that its inhibition efficiency was 280-fold that in the untreated group (9)"
a(CHEBI:darunavir) -| path(MESH:"Virus Replication")

SET Evidence = "Other potential drugs include type II transmembrane serine protease (TMSPSS2) inhibitors and BCR-ABL kinase inhibitor imatinib."
a(CHEBI:imatinib) -| p(HGNC:TMPRSS2)
a(CHEBI:imatinib) -| p(HGNC:ABL1)
a(CHEBI:imatinib) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")

SET Evidence = "Imatinib has anticoronal activity primarily because it inhibits the fusion of virions with the endosomal membrane (18)."
a(CHEBI:imatinib) -| bp(GO:"fusion of virus membrane with host endosome membrane")

SET Evidence = "These agents are indinavir, saquinavir, lopinavir, carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplatovir, presatovir, abacavir, bortezomib, elvitegravir, maribavir, raltegravir, montelukast, deoxyrhapontin, polydatin, chalcone, disulfiram, carmofur, shikonin, ebselen, tideglusib, PX-12, TDZD-8, cyclosporin A, and cinanserin."
SET Study = "in silico"
a(CHEBI:indinavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:saquinavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:lopinavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:carfilzomib) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:ritonavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:121304016) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:atazanavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:darunavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:tipranavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:fosamprenavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:58406357) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:58029842) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:abacavir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:bortezomib) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:elvitegravir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:471161) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:raltegravir) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:montelukast) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:5316606) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:5281718) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:chalcone) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:disulfiram) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:Carmofur) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:Shikonin) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:ebselen) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:11313622) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:219104) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:4124851) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(CHEBI:"cyclosporin A") -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
a(PUBCHEM:5475158) -| a(TAX:"Severe acute respiratory syndrome coronavirus 2")
UNSET Study
UNSET PublicationType
UNSET PublicationStatus
UNSET Section

############################################################################################
# SET DOCUMENT Authors = "Yojana Gadiya"

SET Evidence = "IFN-α is a broad-spectrum antiviral that is usually used  to  treat  hepatitis,  though  it  is  reported  to  inhibit  SARS-CoV reproduction in vitro (4)."
#DB05258 - interferon-alpha
a(DRUGBANK:DB05258) isA a(MESH:"Antiviral Agents")
a(DRUGBANK:DB05258) neg path(DO:hepatitis)
SET MeSHDisease = "Severe Acute Respiratory Syndrome"
a(DRUGBANK:DB05258) -| bp(GOBP:"viral genome replication")
UNSET MeSHDisease

SET Evidence = "Lopinavir/ritonavir is  a  medication  for  the  human  immunodeficiency  virus  (HIV)  used  in  combination  with  other  medications  to  treat  adults  and  children  over  14  days  of  age  who  are  infected with HIV-1 (5). Chu et al. found that lopinavir/ritonavir  has  anti-SARS-CoV  activity  in  vitro  and  in  clinical  studies  (6)."
composite(a(CHEBI:lopinavir),a(CHEBI:ritonavir)) neg path(DO:"human immunodeficiency virus infectious disease")
# composite(a(CHEBI:lopinavir),a(CHEBI:ritonavir)) -| act(a(MESH:"SARS Virus"))

SET Evidence = "Ribavirin  is  a  nucleoside  analogue  with  a  broad-spectrum  of  antiviral  effects.  A  study  compared  111  patients  with  severe  acute  respiratory  syndrome  (SARS)  treated  with  ribavirin  monotherapy  and  41  patients  with  SARS  treated  with  lopinavir/ritonavir and ribavirin; patients treated with the combined therapy  had  a  lower  risk  of  acute  respiratory  distress  syndrome  (ARDS)  and  death  (6)."
# a(CHEBI:ribavirin) -- act(a(MESH:"Antiviral Agents"))
a(CHEBI:ribavirin) -| path(EFO:"acute respiratory distress syndrome")
a(CHEBI:ribavirin) -| path(MESH:Death)
composite(a(CHEBI:lopinavir),a(CHEBI:ritonavir)) -| path(EFO:"acute respiratory distress syndrome")
composite(a(CHEBI:lopinavir),a(CHEBI:ritonavir)) -| path(MESH:Death)

SET Evidence = "Chloroquine  is  a  widely used antimalarial that was found to be a potential broad-spectrum  antiviral  in  2006  (7).  Chloroquine  was  found  to  block  SARS-CoV-2  infection  at  low-micromolar concentration, with a half-maximal effective concentration  (EC50) of 1.13 μM and a half-cytotoxic concentration  (CC50) greater than 100 μM (8)."
a(CHEBI:chloroquine) isA a(MESH:Antimalarials)
# act(a(CHEBI:chloroquine)) -- a(MESH:"Antiviral Agents")
a(CHEBI:chloroquine) -| path(DO:"COVID-19")

SET Evidence = "Arbidol  is  an  antiviral  that  can  be  used  to  treat  influenza  virus.  A  study  has  revealed  that  arbidol  can  effectively  inhibit  SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (9)."
#umifenovir - arbidol
a(CHEBI:umifenovir) isA a(MESH:"Antiviral Agents")
a(CHEBI:umifenovir) neg path(EFO:"influenza infection")
a(CHEBI:umifenovir) -| path(DO:"COVID-19")

SET Evidence = "Favipiravir is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. In addition to its anti-influenza  virus  activity,  favipiravir  is  capable  of  blocking  the  replication  of  flavi-,  alpha-,  filo-,  bunya-,  arena-, noro-, and other RNA viruses (10)."
a(CHEBI:favipiravir) -| a(MESH:"RNA Replicase")
# act(a(CHEBI:favipiravir)) neg path(EFO:"influenza infection")
a(CHEBI:favipiravir) neg path(MESH:"Flavivirus Infections")
a(CHEBI:favipiravir) neg path(MESH:"Alphavirus Infections")
a(CHEBI:favipiravir) neg path(MESH:"Filoviridae Infections")
a(CHEBI:favipiravir) neg path(MESH:"Bunyaviridae Infections")
a(CHEBI:favipiravir) neg path(MESH:"Arenaviridae Infections")
a(CHEBI:favipiravir) neg path(MESH:"Caliciviridae Infections")
a(CHEBI:favipiravir) neg path(MESH:"RNA Virus Infections")

SET Evidence = "Favipiravir  is  converted  into  an  active  phosphoribosylated  form  (favipiravir-RTP)  in  cells  and  is  recognized  as  a  substrate by viral RNA polymerase, thus inhibiting RNA polymerase activity (11)."
#phosphoribosylated
# a(CHEBI:favipiravir) -> act(a(CHEBI:favipiravir))
# act(a(CHEBI:favipiravir)) -> complex(a(CHEBI:favipiravir),a(MESH:"RNA Replicase"))
# complex(a(CHEBI:favipiravir),a(MESH:"RNA Replicase")) -| act(a(MESH:"RNA Replicase"))

SET Evidence = "Remdesivir  is  a  nucleoside  analogue  and  a  broad-spectrum  antiviral.  Animal  experiments  (13)  indicated  that  remdesivir  can  effectively  reduce  the  viral load in lung tissue of mice infected with MERS-CoV,  improve  lung  function,  and  alleviate  pathological  damage to lung tissue."
#121304016 - remdesivir
a(PUBCHEM:121304016) isA a(MESH:"Antiviral Agents")
#in MERS
SET Species = "10090"
SET MeSHAnatomy = "Lung"
a(PUBCHEM:121304016) -| path(MESH:"Viral Load")
# a(PUBCHEM:121304016) -> act(a(MESH:Lung))
a(PUBCHEM:121304016) -| path(MESH:"Lung Injury")
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "Wang et al. found that remdesivir potently  blocks  SARS-CoV-2  infection  at  low-micromolar  concentrations  and  has  a  high  selectivity  index (half-maximal effective concentration (EC50), 0.77 μM; half-cytotoxic concentration (CC50) > 100 μM; SI >  129.87)  (8)."
#121304016 - remdesivir
a(PUBCHEM:121304016) -| path(DO:"COVID-19")

SET Evidence = "Studies  have  also  revealed  some  other  drugs  may  have  potential  efficacy  in  treating  COVID-19.  One  is  darunavir,  which  is  a  second-generation  of  HIV-1  protease  inhibitor.  On  February  4,  2020,  researchers  in  China  announced  that  darunavir  inhibited  SARS-CoV-2  infection in  vitro  (9).  Cell  experiments  indicated  that  darunavir  significantly  inhibited  viral  replication  at  a  concentration of 300 μM in  vitro  and  that  its  inhibition  efficiency  was  280-fold  that  in  the  untreated  group  (9)."
a(CHEBI:darunavir) isA a(MESH:"HIV Protease Inhibitors")
a(CHEBI:darunavir) -| path(DO:"COVID-19")
a(CHEBI:darunavir) -| bp(MESHPP:"Virus Replication")

SET Evidence = "Other  potential  drugs  include  type  II  transmembrane  serine protease (TMSPSS2) inhibitors and BCR-ABL kinase  inhibitor  imatinib."
a(CHEBI:imatinib) -| p(HGNC:TMPRSS2)
a(CHEBI:imatinib) -| p(MESH:"Fusion Proteins, bcr-abl")

SET Evidence = "Hoffmann  et  al.  indicated  that  SARS-CoV-2  uses  the  SARS-CoV  receptor,  ACE2,  and the cellular protease TMPRSS2 to enter target cells."
p(HGNC:ACE2) -- bp(FIXME:"SARS-CoV-2 entry")
p(HGNC:TMPRSS2) -- bp(FIXME:"SARS-CoV-2 entry")

SET Evidence = "Imatinib  has  anti-coronal activity primarily because it inhibits the fusion of virions with the endosomal membrane (18)."
a(CHEBI:imatinib) -| bp(GOBP:"fusion of virus membrane with host endosome membrane")

SET Evidence = "A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  reported  30  agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020  (19).  These  agents  are  indinavir,  saquinavir,  lopinavir,  carfilzomib,  ritonavir,  remdesivir,  atazanavir,  darunavir,  tipranavir,  fosamprenavir,  enzaplatovir,  presatovir,  abacavir,  bortezomib,  elvitegravir,  maribavir, raltegravir, montelukast,  deoxyrhapontin,  polydatin,  chalcone,  disulfiram,  carmofur,  shikonin,  ebselen,  tideglusib,  PX-12,  TDZD-8,  cyclosporin  A,  and  cinanserin. The  same  study  also  found  that  Chinese  herbal  medicines  such  as  Rhizoma  Polygoni  Cuspidati  and  Radix  Sophorae  Tonkinensis  may  contain  active  ingredients  against  SARS-COV-2 (19). "
#58406357 - enzaplatovir, DB12165 - presatovir, DB06234 - maribavir, DB06817 - raltegravir, 5316606 - deoxyrhapontin, trans-piceid - polydatin, DB12129 - tideglusib, DB05448 - PX-12, 4124851 - TDZD-8, Pinellia  - Rhizoma Polygoni  Cuspidati
a(CHEBI:indinavir) neg path(DO:"COVID-19")
a(CHEBI:saquinavir) neg path(DO:"COVID-19")
a(CHEBI:carfilzomib) neg path(DO:"COVID-19")
a(CHEBI:atazanavir) neg path(DO:"COVID-19")
a(CHEBI:tipranavir) neg path(DO:"COVID-19")
a(CHEBI:fosamprenavir) neg path(DO:"COVID-19")
a(PUBCHEM:58406357) neg path(DO:"COVID-19")
a(DRUGBANK:DB12165) neg path(DO:"COVID-19")
a(CHEBI:abacavir) neg path(DO:"COVID-19")
a(CHEBI:bortezomib) neg path(DO:"COVID-19")
a(CHEBI:elvitegravir) neg path(DO:"COVID-19")
a(DRUGBANK:DB06234) neg path(DO:"COVID-19")
a(DRUGBANK:DB06817) neg path(DO:"COVID-19")
a(CHEBI:montelukast) neg path(DO:"COVID-19")
a(PUBCHEM:5316606) neg path(DO:"COVID-19")
a(CHEBI:"trans-piceid") neg path(DO:"COVID-19")
a(CHEBI:chalcone) neg path(DO:"COVID-19")
a(CHEBI:disulfiram) neg path(DO:"COVID-19")
a(CHEBI:Carmofur) neg path(DO:"COVID-19")
a(CHEBI:Shikonin) neg path(DO:"COVID-19")
a(CHEBI:ebselen) neg path(DO:"COVID-19")
a(DRUGBANK:DB12129) neg path(DO:"COVID-19")
a(DRUGBANK:DB05448) neg path(DO:"COVID-19")
a(PUBCHEM:4124851) neg path(DO:"COVID-19")
a(CHEBI:"cyclosporin A") neg path(DO:"COVID-19")
a(MESH:Cinanserin) neg path(DO:"COVID-19")
a(MESH:Pinellia) neg path(DO:"COVID-19")
a(MESH:Sophora) neg path(DO:"COVID-19")
